

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/657,363 |
| Filing Date | September 8, 2003 |
| First Named Inventor | Young et al. |
| Art Unit | 1648 |
| Examiner Name | Hill, Myron G. |
| Attorney Docket No. | 10271-159-999 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Document Number – Kind Code | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|-------------|--------------------------------|-----------------------------------|--|---|
| | J01 | 4,517,304 | 05/14/1985 | Stott et al. | |
| | J02 | 4,526,938 | 07/2/1985 | Churchhill et al. | |
| | J03 | 4,659,563 | 04/21/1987 | Dobkin | |
| | J04 | 4,717,766 | 01/05/1988 | Dobkin | |
| | J05 | 4,760,026 | 07/26/1988 | Lennox et al. | |
| | J06 | 4,853,326 | 08/01/1989 | Quash et al. | |
| | J07 | 4,917,893 | 04/17/1990 | Okada et al. | |
| | J08 | 5,071,758 | 12/10/1991 | Stott et al. | |
| | J09 | 5,128,326 | 07/07/1992 | Balazs et al. | |
| | J10 | 5,137,804 | 08/11/1992 | Greene et al. | |
| | J11 | 5,149,650 | 09/22/1992 | Wertz et al. | |
| | J12 | 5,183,657 | 02/2/1993 | Buurman | |
| | J13 | 5,194,595 | 03/16/1993 | Wathen | |
| | J14 | 5,219,996 | 06/15/1993 | Bodmer et al. | |
| | J15 | 5,223,254 | 06/29/1993 | Paradiso et al. | |
| | J16 | 5,240,694 | 08/31/1993 | Gwaltney, Jr. | |
| | J17 | 5,271,927 | 12/21/1993 | Parker et al. | |
| | J18 | 5,279,935 | 01/18/1994 | Nycz | |
| | J19 | 5,288,630 | 02/22/1994 | Wathen | |
| | J20 | 5,332,567 | 07/26/1994 | Goldenberg | |
| | J21 | 5,332,805 | 07/26/1994 | Carey et al. | |
| | J22 | 5,340,926 | 08/23/1994 | Lowe et al. | |
| | J23 | 5,354,554 | 10/11/1994 | Rhind | |
| | J24 | 5,391,478 | 02/21/1995 | Greene et al. | |
| | J25 | 5,411,749 | 05/2/1995 | Mayo et al. | |
| | J26 | 5,412,077 | 05/2/1995 | Siber et al. | |

LA1-3012585v2

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/657,363 |
| Filing Date | September 8, 2003 |
| First Named Inventor | Young et al. |
| Art Unit | 1648 |
| Examiner Name | Hill, Myron G. |
| Attorney Docket No. | 10271-159-999 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Document Number – Kind Code | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|-------------|--------------------------------|-----------------------------------|--|---|
| | J27 | 5,418,136 | 05/23/1995 | Miller et al. | |
| | J28 | 5,422,097 | 06/06/1995 | Gwaltney Jr. | |
| | J29 | 5,424,189 | 06/13/1995 | Oberst et al. | |
| | J30 | 5,468,606 | 11/21/1995 | Bogart et al. | |
| | J31 | 5,470,736 | 11/28/1995 | Verma et al. | |
| | J32 | 5,476,997 | 12/19/1995 | Kaneshima et al. | |
| | J33 | 5,484,893 | 01/16/1996 | Parker et al. | |
| | J34 | 5,506,209 | 04/09/1996 | Mukerji et al. | |
| | J35 | 5,518,725 | 05/21/1996 | Daynes et al. | |
| | J36 | 5,530,102 | 06/25/1996 | Gristina et al. | |
| | J37 | 5,538,733 | 07/23/1996 | Emery et al. | |
| | J38 | 5,538,952 | 07/23/1996 | Mukerji et al. | |
| | J39 | 5,624,821 | 04/29/1997 | Winter | |
| | J40 | 5,648,260 | 07/15/1997 | Winter | |
| | J41 | 5,679,377 | 10/21/1997 | Bernstein et al. | |
| | J42 | 5,855,913 | 01/05/1999 | Hanes et al. | |
| | J43 | 5,874,064 | 02/23/1999 | Edwards et al. | |
| | J44 | 5,912,015 | 06/15/1999 | Bernstein et al. | |
| | J45 | 5,916,597 | 06/29/1999 | Lee et al. | |
| | J46 | 5,934,272 | 08/10/1999 | Lloyd et al. | |
| | J47 | 5,985,309 | 11/16/1999 | Edwards et al. | |
| | J48 | 5,985,320 | 11/16/1999 | Edwards et al. | |
| | J49 | 5,989,463 | 11/23/1999 | Tracy et al. | |
| | J50 | 6,019,968 | 02/01/2000 | Platz et al. | |
| | J51 | 6,121,022 | 09/19/2000 | Presta | |
| | J52 | 6,194,551 | 02/27/2001 | Idusogie | |

LAI-3012585v2

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/657,363 |
| Filing Date | September 8, 2003 |
| First Named Inventor | Young et al. |
| Art Unit | 1648 |
| Examiner Name | Hill, Myron G. |
| Attorney Docket No. | 10271-159-999 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Document Number – Kind Code | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|----------|-----------------------------|-----------------------------|---|---|
| | J53 | 6,277,375 | 08/21/2001 | Ward | |
| | J54 | 6,519,948 | 02/18/2003 | Zorn | |
| | J55 | 6,528,624 | 03/04/2003 | Idusogie | |
| | J56 | 6,538,124 | 03/25/2003 | Idusogie | |
| | J57 | 6,565,888 | 05/20/2003 | Tracy et al. | |
| | J58 | 6,737,056 | 05/18/2004 | Presta | |
| | J59 | 7,083,784 | 08/01/2006 | Dall'Acqua | |
| | J60 | 7,416,726 | 08/26/2008 | Ravetch | |
| | J61 | 2004-0131609 | 07/08/2004 | Young et al. | |
| | J62 | 2004-0002587 | 01/01/2004 | Watkins | |
| | J63 | US 2006-0099220 | 05/11/2006 | Tous et al. | |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Foreign Patent Document Country Code, Number, Kind Code (if known) | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|--|-----------------------------|---|---|---|
| | K01 | AU 2002219944 | 02/21/2008 | MedImmune, Inc. | | |
| | K02 | EP 0413622 | 02/20/1991 | Rhone Poulenc Rorer SA | | |
| | K03 | EP 0451216 | 01/24/1996 | Protein Design Labs Inc | | |
| | K04 | EP 0682040 | 11/15/1995 | Protein Design Labs Inc | | |
| | K05 | WO 00/42072 | 07/20/2000 | Genentech Inc. | | |
| | K06 | WO 01/58957 | 08/16/2001 | Lexigen Pharm. Corp. | | |
| | K07 | WO 03/054213 | 07/03/2003 | Genentech Inc. | | |
| | K08 | WO 04/010935 | 02/05/2004 | MedImmune | | |
| | K09 | WO 04/029207 | 04/08/2004 | Xencor et al. | | |
| | K10 | WO 04/035752 | 04/29/2004 | Protein Design Labs, Inc. | | |

LAI-3012585v2

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/657,363 |
| Filing Date | September 8, 2003 |
| First Named Inventor | Young et al. |
| Art Unit | 1648 |
| Examiner Name | Hill, Myron G. |
| Attorney Docket No. | 10271-159-999 |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Foreign Patent Document Country Code, Number, Kind Code (if known) | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|--|-----------------------------|--|---|---|
| | K11 | WO 06/034292 | 03/30/2006 | MedImmune | | |
| | K12 | WO 90/07861 | 07/26/1990 | Protein Design Labs, Inc. | | |
| | K13 | WO 91/05548 | 05/02/1991 | Pitman-Moore Inc. | | |
| | K14 | WO 93/05796 | 04/01/1993 | The Scripps Research Institute | | |
| | K15 | WO 93/15200 | 08/05/1993 | Rhone Poulenc Rorer SA | | |
| | K16 | WO 93/19197 | 09/30/1993 | Immunet | | |
| | K17 | WO 93/20210 | 10/14/1993 | Scotgen Limited | | |
| | K18 | WO 95/04081 | 02/09/1995 | Oravax, Inc. | | |
| | K19 | WO 96/20698 | 07/11/1996 | The Board of Regents acting for and on behalf of The University Of Michigan | | |
| | K20 | WO 97/32572 | 09/12/1997 | The Penn State Research Foundation of Massachusetts Institute Of Technology | | |
| | K21 | WO 97/34631 | 09/25/1997 | Board Of Regents, The University Of Texas System Ward | | |
| | K22 | WO 97/44013 | 11/27/1997 | Massachusetts Institute Of Technology The Penn State Research Foundation | | |
| | K23 | WO 98/23289 | 06/04/1998 | The General Hospital Corp. | | |
| | K24 | WO 98/31346 | 07/23/1998 | Massachusetts Institute Of Technology; The Penn State Research Foundation | | |
| | K25 | WO 99/15154 | 04/01/1999 | Alkermes Controlled Therapeutics, Inc. | | |
| | K26 | WO 99/20253 | 04/29/1999 | Bioglan Therapeutics AB | | |
| | K27 | WO 99/51642 | 10/14/1999 | Genentech Inc. | | |
| | K28 | WO 99/66903 | 12/29/1999 | Advanced Inhalation Research, Inc. | | |
| | K29 | WO 07/002543 | 01/04/2007 | MedImmune | | |
| | K30 | WO 09/003019 | 12/31/2008 | MedImmune | | |

LAI-3012585v2

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

| | | |
|---|-----------------------------|-------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | Application Number | 10/657,363 |
| | Filing Date | September 8, 2003 |
| | First Named Inventor | Young et al. |
| | Art Unit | 1648 |
| | Examiner Name | Hill, Myron G. |
| | Attorney Docket No. | 10271-159-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
| | L01 | Adams et al., 1998. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies, Cancer Res. 58(3):485-90. | |
| | L02 | American Academy of Pediatrics Committee on Infectious Diseases: Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection. Pediatrics. 1993 Sep;92(3):501-4. | |
| | L03 | Bennett et al., 2007. Immunopathogenesis of Respiratory Syncytial Virus Bronchiolitis, JID, 195:1532-1540. | |
| | L04 | Bentley and Rabbits, 1980. Human immunoglobulin variable region genes-- DNA Sequences of Two V Kappa Genes and a Pseudogene, Nature 288: 730-733. | |
| | L05 | Boulianne et al., 1984. Production of functional chimaeric mouse/human antibody, Nature 312(5995):643-646. | |
| | L06 | Carson and Freemark, 1986. Human lymphocyte hybridomas and monoclonal antibodies, Adv. Immunol. 38:275-311. | |
| | L07 | Chothia et al., 1998. Structural determinants in the sequences of immunoglobulin variable domain. J Mol Biol. 278(2):457-79. | |
| | L08 | Cleek et al., 1997. Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application, Pro. Int'l Symp. Control. Rel Bioact. Mater. 24: 853-854. | |
| | L09 | Colman, 1994. Effects of amino acid sequence changes on antibody-antigen interactions; Res Immunol. 145(1):33-6. | |
| | L10 | Crowe et al., 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice, Proc. Natl. Acad. Sci. USA, 91:1386-1390. | |
| | L11 | DeVincenzo, 2005. Factors Predicting Childhood Respiratory Syncytial Virus Severity. What They Indicate About Pathogenesis. The Pediatric Infectious Disease Journal, 24(11):S177-S183. | |
| | L12 | Downham et al., 1976. Breast-feeding protects against respiratory syncytial virus infections. Br Med J. 2(6030):274-6. | |
| | L13 | Edelman et al., 1969. The Covalent Structure of an Entire gammaG Immunoglobulin Molecule. PNAS 63:78-85. | |
| | L14 | Fields et al., 1990, Fields Virology, 2nd Ed., Vol. 1, Raven Press, NY p. 1045-1072. | |
| | L15 | Garvie and Gray, 1980. Outbreak of Respiratory Syncytial Virus Infection in the Elderly, Br Med J. 281(6250):1253-4. | |
| | L16 | Gillies et al., 1989. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol Methods. 125:191-202. | |
| | L17 | Hemming et al., 1988. Topically Administered Immunoglobulin Reduces Pulmonary Respiratory Syncytial Virus Shedding in Owl Monkeys. Antimicrobial Agents and Chemotherapy, 32(8):1269-1270. | |
| | L18 | Howard et al., 1989. Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits, J Neurosurg. 71(1):105-12. | |
| | L19 | Hudson and Souriau, 2003. Engineered Antibodies. Nature Medicine 9(1):129-34. | |
| | L20 | Ichiyoshi et al., 1995. A human anti-insulin IgG autoantibody apparently arises through clonal selection from an insulin-specific "germ-line" natural antibody template. Analysis by V gene segment reassortment and site-directed mutagenesis, J. Immunol. 154(1):226-38. | |
| | L21 | Jackson et al., 1998. Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives, Br. J. Cancer 78(2):181-8. | |

LAI-3012585v2

| | |
|---|------------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/657,363 |
| Filing Date | September 8, 2003 |
| First Named Inventor | Young et al. |
| Art Unit | 1648 |
| Examiner Name | Hill, Myron G. |
| Attorney Docket No. | 10271-159-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
| | L22 | Johnson et al., 1987. The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins, Proc Natl Acad Sci U S A. 84(16):5625-9. | |
| | L23 | Johnson et al., 1991. Development of humanized monoclonal antibodies which neutralize respiratory syncytial virus. J. Cellular Biochem. Suppl. 15E. P.120, Abstract No. 108. | |
| | L24 | Kapikian et al., 1969. An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine, Am J Epidemiol. 89(4):405-21. | |
| | L25 | Levy et al., 1985. Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate, Science. 228(4696):190-2. | |
| | L26 | Liu et al., 1987. Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells, Gene 54(1):33-40. | |
| | L27 | Maynard et al., 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity, Nat. Biotechnol. 20(6):597-601. | |
| | L28 | Mejias et al., 2005. Respiratory syncytial virus infections: Old challenges and new opportunities, Ped. Infect. Dis. J. 24: S189-S197. | |
| | L29 | Mejias et al., 2005. Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency, Antimicrobial Agents and Chemotherapy Vol. 49, No. 11: 4700-4707. | |
| | L30 | Morrison et al., 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA 81(21):6851-6855. | |
| | L31 | Morrison et al., 1985. Transfectomas provide novel chimeric antibodies, Science 229(4719):1202-1207. | |
| | L32 | Murphy et al., 1994. An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines, Virus Res. 32(1):13-36. | |
| | L33 | Ning et al., 1996. Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel, Radiotherapy and Oncology 39: 179-89. | |
| | L34 | Ogra et al., 1988. Respiratory Syncytial Virus Infection and the Immunocompromised Host, Pediatr Infect Dis J. 1988 Apr;7(4):246-9. | |
| | L35 | Orkin and Motulsky, Report and recommendations of the panel to assess the NIH investment in research on gene therapy, available from http://www.nih.gov/news/panelrep.html (1995). | |
| | L36 | Padlan, 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28(4/5):489-498. | |
| | L37 | Pohl et al., 1992. Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients, J Infect Dis. 165(1):166-9. | |
| | L38 | Press et al., 1970. The Amino Acid Sequences of the Fd Fragments of Two Human Gamma-1 Heavy chains, Biochem J. 117(4):641-60. | |
| | L39 | Prince et al., 1987. Effectiveness of Topically Administered Neutralizing Antibodies in Experimental Immunotherapy of Respiratory Syncytial Virus Infection in Cotton Rats, Journal of Virology. 61(6):1851-1854. | |
| | L40 | Riechmann et al., 1988. Reshaping human antibodies for therapy. Nature. 332(6162):323-7. | |
| | L41 | Ruuskanen et al., 1993. Respiratory syncytial virus, Curr Probl Pediatr. 23(2):50-79. | |

LAI-3012585v2

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/657,363 |
| Filing Date | September 8, 2003 |
| First Named Inventor | Young et al. |
| Art Unit | 1648 |
| Examiner Name | Hill, Myron G. |
| Attorney Docket No. | 10271-159-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|---|---|
| | L42 | Saudek et al., 1989. A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery. N Engl J Med. 321(9):574-9. | |
| | L43 | Scott et al., 1985. Cellular reactivity to respiratory syncytial virus in human colostrum and breast milk. J Med Virol. 17(1):83-93. | |
| | L44 | Sefton, 1987. Implantable Pumps, CRC Crit. Rev. Biomed. Eng. 14:201-240. | |
| | L45 | Sevier et al., 1981. Monoclonal antibodies in clinical immunology. Clin Chem. 27(11):1797-806. | |
| | L46 | Song et al., 1995. Antibody Mediated Lung Targeting of Long-Circulating Emulsions, PDA Journal of Pharmaceutical Science & Technology 50: 372-77. | |
| | L47 | Studnicka et al., 1994. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng. 7:805-814. | |
| | L48 | Taylor et al., 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology. 52(1):137-42. | |
| | L49 | Taylor et al., 1992. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol. 73 (Pt 9):2217-23. | |
| | L50 | Van Wyke Coelingh et al., 1985. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus, Virology 143(2):569-582. | |
| | L51 | Verma et al., 1997. Gene therapy - promises, problems and prospects, Nature 389:239-242. | |
| | L52 | Wald et al., 1988. In re ribavirin: a case of premature adjudication? J. Pediatr. 112(1):154-158. | |
| | L53 | Walsh et al., 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 43(2):756-8. | |
| | L54 | Watkins et al., 1997. Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay. Anal Biochem. 253(1):37-45. | |
| | L55 | Wright et al., 1982. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children, Infect. Immun. 37(1):397-400. | |
| | L56 | Wu et al., 2008. Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab in Human Antibody Therapeutics for Viral Disease. Current Topics in Microbiology and Immunology 317. Springer-Verlag Berlin Heidelberg, p. 103-123. | |
| | L57 | U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Interview Summary dated 03/27/2009 | |
| | L58 | U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 01/22/2009 | |

/Myron Hill/

06/21/2009

LAI-3012585v2

**EXAMINER
SIGNATURE**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/